AR122142A1 - Compuestos heterocíclicos - Google Patents
Compuestos heterocíclicosInfo
- Publication number
- AR122142A1 AR122142A1 ARP210101386A ARP210101386A AR122142A1 AR 122142 A1 AR122142 A1 AR 122142A1 AR P210101386 A ARP210101386 A AR P210101386A AR P210101386 A ARP210101386 A AR P210101386A AR 122142 A1 AR122142 A1 AR 122142A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- formula
- ring
- further substituted
- independently selected
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 4
- 101000996780 Homo sapiens Probable G-protein coupled receptor 139 Proteins 0.000 abstract 2
- 102100033836 Probable G-protein coupled receptor 139 Human genes 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- DBTILJBQGWZREL-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]imidazol-2-one Chemical group ClC1=CC=CC(N2C(N(CC=3OC(=NN=3)C=3C=CC=CC=3)C=C2)=O)=C1 DBTILJBQGWZREL-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020090110A JP2021183586A (ja) | 2020-05-22 | 2020-05-22 | 複素環化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122142A1 true AR122142A1 (es) | 2022-08-17 |
Family
ID=76797025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101386A AR122142A1 (es) | 2020-05-22 | 2021-05-20 | Compuestos heterocíclicos |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12630534B2 (enExample) |
| EP (1) | EP4153583B1 (enExample) |
| JP (3) | JP2021183586A (enExample) |
| AR (1) | AR122142A1 (enExample) |
| ES (1) | ES3001126T3 (enExample) |
| WO (1) | WO2021234450A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021183586A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2021183587A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2025510009A (ja) * | 2022-02-28 | 2025-04-14 | シロナックス リミテッド． | Ｒｉｐ１調節物質、その調製、及び使用 |
| CN117815217B (zh) * | 2023-12-29 | 2026-07-10 | 郑州大学第三附属医院(河南省妇幼保健院) | 一种苯甲酰胺衍生物改善认知功能障碍的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1194449B1 (en) | 1999-06-28 | 2010-09-22 | Oklahoma Medical Research Foundation | Inhibitors of memapsin 2 and use thereof |
| AR052342A1 (es) | 2004-12-21 | 2007-03-14 | Janssen Pharmaceutica Nv | Derivados sustituidos de triazolona,tetrazolona e imidazolona con actividad selectiva antagonista de alfa2c-adenoreceptores |
| US8148367B2 (en) | 2007-01-12 | 2012-04-03 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| WO2008094556A2 (en) | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
| WO2011145735A1 (ja) | 2010-05-21 | 2011-11-24 | 武田薬品工業株式会社 | チアゾール誘導体 |
| JP6779214B2 (ja) * | 2015-01-09 | 2020-11-04 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｒｏｃｋ阻害剤としての環状ウレア |
| WO2020097609A1 (en) | 2018-11-09 | 2020-05-14 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
| JP7199940B2 (ja) | 2018-12-03 | 2023-01-06 | 川崎重工業株式会社 | 複合材料製航空機用部品およびその製造方法 |
| JP2021183586A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2021183587A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
-
2020
- 2020-05-22 JP JP2020090110A patent/JP2021183586A/ja active Pending
-
2021
- 2021-05-20 US US17/999,505 patent/US12630534B2/en active Active
- 2021-05-20 ES ES21737768T patent/ES3001126T3/es active Active
- 2021-05-20 WO PCT/IB2021/000336 patent/WO2021234450A1/en not_active Ceased
- 2021-05-20 JP JP2022570530A patent/JP7734152B2/ja active Active
- 2021-05-20 EP EP21737768.8A patent/EP4153583B1/en active Active
- 2021-05-20 AR ARP210101386A patent/AR122142A1/es unknown
-
2025
- 2025-08-25 JP JP2025139598A patent/JP2025168429A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP4153583B1 (en) | 2024-10-30 |
| ES3001126T3 (es) | 2025-03-04 |
| JP2025168429A (ja) | 2025-11-07 |
| US20230348435A1 (en) | 2023-11-02 |
| WO2021234450A1 (en) | 2021-11-25 |
| EP4153583A1 (en) | 2023-03-29 |
| TW202208349A (zh) | 2022-03-01 |
| JP7734152B2 (ja) | 2025-09-04 |
| EP4153583C0 (en) | 2024-10-30 |
| JP2023528280A (ja) | 2023-07-04 |
| JP2021183586A (ja) | 2021-12-02 |
| US12630534B2 (en) | 2026-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR122143A1 (es) | Compuestos heterocíclicos | |
| UY28578A1 (es) | Derivados de amida | |
| PE20242071A1 (es) | Compuestos moduladores de diacilglicerol quinasa | |
| PE20161400A1 (es) | Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer | |
| JP5615902B2 (ja) | イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体 | |
| BRPI0924126A2 (pt) | composto heterocíclico bicíclico | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| AR041378A1 (es) | 4- (indazol-3 il) fenoles substituidos | |
| AR066421A1 (es) | Compuestos derivados de piridona | |
| AR119234A1 (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
| AR067904A1 (es) | Derivados de piperazina-amida | |
| PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| CN111601797A (zh) | 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 | |
| BRPI0607600A2 (pt) | derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina | |
| BRPI0519287A2 (pt) | derivados de amida | |
| AR062405A1 (es) | Derivados de isoindol | |
| EP2970223A1 (en) | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use | |
| DK171133B1 (da) | 1-Pyridyl- eller -pyrimidyl-4-substitueret alkyl-piperaziner eller -homopiperaziner, fremstilling af disse, samt farmaceutiske præparater indeholdende disse | |
| AR034585A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos | |
| PE20080191A1 (es) | Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 | |
| AR082534A1 (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes | |
| PY19100637A (es) | Compuestos químicos | |
| PE20081495A1 (es) | Derivados 4,5-difenilpirrol-2-carboxamida como antagonistas de los receptores cb1 | |
| AR121666A1 (es) | DERIVADOS DE NAFTIRIDINA Y PIRIDO[3,4-C]PIRIDAZINA COMO MODULADORES DEL RECEPTOR GABAA a5 |